Myriapod NGS Dry line includes NGS panels for DNA and RNA sequencing dedicated to the study of predictive- diagnostic SNV (SNP, In/del, fusions) clinically relevant in the most frequent cancer types as: colon, lung, melanoma, central nervous system, GIST, thyroid, and bladder, and also independent tissue biomarkers, like NTRK 1, 2 and 3 gene fusions.

Main features:

  • Ready to use: Dry, ready-to-use, in pre-aliquoted strip reagent format
  • Simple: the easiest and fastest workflow on the market for NGS libraries preparation, with a hands-on time < 2 hours and a turnaround time, from sample to sequencing, of 8 hours.
  • Flexible: optimized on Illumina® Miseq™, MiniSeq™ and iSeql100™ with the flexibility to test from 2 to 46 samples/run.
  • Low amount and quality of input: validated to work from 10 ng/reactions of DNA and RNA extracted from FFPE or cfDNA.
  • Certified: fully CE-IVD protocol, from sample to result with data processing through Myriapod® NGS Data Analysis Software, fully automatic, bioinformatic analysis local system without any needs to send out data or use cloud based solutions.

Myriapod® NGS data Analysis: the CE-IVD solution for local NGS data analysis

Myriapod® NGS Data Analysis is a complete, in vitro diagnostic and easy-to-use bioinformatics solution, which come with the Myriapod® NGS Data Analysis Software and its own dedicated workstation. Myriapod NGS solution provides simplicity in the analysis for fast and easy reporting. Further, the data management system offers the highest level of security with a completely localized data analysis, so sensitive data is not sent over the network or to a cloud system. Myriapod NGS Data Analysis solution complies with all the EU General Data Protection Regulations (GDPR).

Principle of the method: the Myriapod® NGS Cancer panel DNA kit allows the preparation of Next Generation Sequencing (NGS) libraries compatible with the Illumina “MiSeq®”, “MiniSeq™” and “iSeq™ 100” platforms for the identification of SNV and indels in 16 clinical diagnostic genes.

Source material: genomic DNA, purified and non-purified, isolated from tumour tissue (fresh, frozen, formalin-fixed including paraffin (FFPE)) or Plasma (cfDNA); extraction reagents included in the kit for DNA extraction from FFPE samples can be used.

Intended Use: CE IVD workflow from extraction to bionformatics analysis of 16 genes whose alterations are implicated in numerous tumour types.

Genes included in the panel:

Principle of the method: The Myriapod NGS Cancer panel RNA” kit allows the preparation of Next Generation Sequencing (NGS) libraries compatible with the Illumina “MiSeq”, “MiniSeq™” and “iSeq™ 100” platforms for the identification of more than 1000 fusion events in 10 clinical diagnostic genes.

Source material: RNA isolated from tumor tissue (fresh, frozen, formalin-fixed including paraffin (FFPE)) or from needle-asporates (FNA).

Intended use: CE IVD workflow from extraction to bioinformatics for the study of 10 gene fusions of predictive-diagnostic interest for lung tumors (ROS1, RET, ALK, MET), thyroid (RET, ALK, PPARG), bladder (